45 results about "Lactococcus garvieae" patented technology

The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and / or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the said nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the said nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

A complete nutritional composition comprising Lactococcus strains or probiotic is provided for reducing the symptoms of allergies in different groups of patients such as allergies originating from food allergens in young children or infants and respiratory allergens in children, adults and household pets. Preferably the composition reduces symptoms of allergies (secondary prevention) while not significantly affecting sensitization (primary prevention). The composition comprises a probiotic of the genus Lactococcus.

The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

The invention relates to a recombinant Lactococcus strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant Lactococcus that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where such medium compounds are present, but cannot survive outside the host organism in the absence of such medium compounds.

Disclosed is an agent for reducing visceral fat, which comprises a cell of a lactic acid bacterium, particularly a lactic acid bacterium belonging to the genus Lactobacillus or Lactococcus and / or a culture of the cell as an active ingredient. The agent can ameliorate the disease condition of metabolic syndrome which is a combination of risk factors including hypertension, hyperlipemia, impaired glucose tolerance and the like, and can also reduce the accumulation of visceral fat. Further disclosed is a food / beverage or feed comprising the agent.

The invention relates to the technical field of feed additive and processing thereof, and in particular to a probiotic feed additive. The probiotic feed additive is prepared by mixing autonomously separated lactobacillus plantarum, candida rugosa, candida ethanolica and lactococcus garvieae and buffalo milk fermentation substrate to ferment. The preparation process disclosed by the invention is simple, and the probiotic feed additive can be widely applied in the raising of livestock and poultry such as milk buffalos, pigs, chickens, cattle and sheep. The probiotic feed additive can remarkably improve the intestinal microbial floras of animals and enhance immunity, and can reduce the usage of antibiotic medicines and eliminate medicine residue, and when applied in production, the probiotic feed additive can shorten feeding periods and save feeds, thus increasing farming income.

The invention discloses a construction method and application of a faeG expressing gene engineering probiotic. The method comprises the following steps of: according to the gene sequence and the expression vector plasmid characteristic of a disclosed F4 escherichia coli pilus adhesin faeG, designing a primer which contains a specific endonuclease site; performing polymerase chain reaction (PCR) amplification by taking deoxyribonucleic acid (DNA) of an enterotoxigenic escherichia coli plasmid as a template to obtain a faeG gene-containing segment, linking the segment with an expression vector plasmid pNZ8148 to obtain a recombinant plasmid pNZ8148-faeG, transferring the recombinant plasmid into lactobacillus or a galactococcus cell by using an electrotransformation method to obtain gene engineering probiotic which expresses enterotoxigenic escherichia coli pilus adhesin faeG, expressing under the induction of nisin and analyzing and proving a target gene by SDS-PAGE and Western blot so as to express correctly. A recombinant strain can be used for preventing colibacillus diarrhea of suckling pigs and weanling pigs.

The invention relates to a lactococcus garviea bacteriocin, a preparing method thereof and an application thereof. The high-yield actococcus garviea bacteriocin can be obtained in the mode that lactococcus garviea is subjected to fermented cultivation, and then the bacteriocin in the cultivating-fermenting liquid is extracted with a pH adsorption method; more than 800 mg of the lactococcus garviea bacteriocin can be prepared through 1 L of the fermenting liquid. The lactococcus garviea bacteriocin has quite high broad-spectrum bacteriostasis capacity and has a quite high inhibiting effect on some gram negative bacteria, some gram positive bacteria, yeast and mould causing human diseases and food spoilage. The lactococcus garviea bacteriocin has the effect of treating and preventing acute and chronic enteritis.

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

The present invention relates to a food composition for alleviating a hangover, the composition containing, as an active ingredient, at least one strain selected from Lactococcus chungangensis, Lactococcus fujiensis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis, and Lactococcus raffinolactis or a culture liquid thereof. Specifically, a functional cream cheese was manufactured using five species of Lactococcus strains above having an ethanol and acetaldehyde degrading function, and this functional cream cheese is preferably used for a functional health food for alleviating a hangover, and, extensively, acetaldehyde, which is an ethanol degradation product, is degraded to minimize the accumulation of acetaldehyde, which is likely to cause cancer in the body. In addition, the functional cream cheese, which is a cheese starter for lowering a unit cost compared with cream cheeses in the market, can be differentiated from cream cheeses sold in the market.

To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.

The present invention pertains to a lactic acid bacterium belonging to the genus Lactococcus and having a receipt number NITE ABP-01694 with the Patent Microorganisms Depositary (NPMD) of the National Institute of Technology and Evaluation (NITE), a natural immunostimulant having this lactic acid bacterium as an active ingredient, a food or drink containing this lactic acid bacterium or this natural immunostimulant, and yogurt containing lactic acid bacteria, wherein the yogurt has resistance to at least one bacterium selected from the group comprising methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus mundtii.

The invention discloses a compound biological fresh-keeping agent and the application thereof. The compound biological fresh-keeping agent is composed of lactococcus garvieae, helianthus tuberosus linn leaf alcohol extract and water-soluble chitosan. Lactococcus garvieae is prepared through fermentation and then extraction of lactococcus garvieae SY-1, and the strain is preserved in the China General Microbiological Culture Collection Center of China Microbe Preservation Management Committee with preservation number of CGMCC NO.9485 on July 28, 2014. The helianthus tuberosus linn leaf alcohol extract is prepared through ultrasonic extraction. The fresh-keeping agent is applied to fresh-keeping of small berries, a safe, poisonous and edible transparent film can be formed on the surface of fruit, and through conventional refrigerator preservation, the color and nutrients of fruit can be effectively maintained and the shelf life of various small berries can be prolonged remarkably.

The present invention provides an equol-producing lactic acid bacteria-containing composition comprising, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol.Such a composition is effective for the prevention and alleviation of malaise inclusive of climacteric disturbance in middle-aged and elderly women for which no effective prophylactic method or alleviating means has heretofore been available.

The invention provides sika deer coronet antibacterial peptides / proteins with antibacterial effect and applications thereof, including sika deer coronet micromolecular polypeptides, sika deer coronet collagen hydrolyzing peptides, and sika deer coronet micromolecular protein monomers. The peptides / proteins are subjected to inhibition ring tests so as to observe the inhibiting effect on Gram-negative bacteria, Gram-positive bacteria, and fungi; wherein the Gram-negative bacteria comprise enterobacter aerogenes, proteus mirabilis, pseudomonas aeruginosa, and escherichia coli. The Gram-positive bacteria comprise staphylococcus lentus, lactococcus garvieae, staphylococcus xylosus, bacillus subtilis, and staphylococcus intermedius. The fungi are candida albicans. Under the effect of various bacteriostatic agents, the enterobacter aerogenes, bacillus subtilis, escherichia coli, pseudomonas aeruginosa, staphylococcus intermedius, and staphylococcus xylosus are inhibited to a certain degree, and the candida albicans, lactococcus garvieae, proteus mirabilis, and staphylococcus lentus are not inhibited.

The present invention discloses novel isolated strains of lactic acid producing bacteria of the genera Lactobacillus and Pediococcus, and a method for isolation of such bacterial strains, having the ability to colonise and become established in a human vagina, even during menstrual discharge. Furthermore, a composition comprising the bacterial strains and a sanitary article comprising the bacterial strains, such as a tampon, for prophylaxis and / or treatment of infections of the urogenital tract, are described. The present invention also describes a method for prophylaxis and / or treatment of infections of the urogenital tract, wherein at least one of the bacterial strains is administered vaginally.

The present disclosure relates to genetic markers for discrimination and detection of bacteria causing Edwardsiellosis and Streptococcosis in fish, and a method for discriminating and detecting the bacteria using the same. A genetic marker for discrimination and / or detection of each of Edwardsiella tarda, Streptococcus iniae, Streptococcus parauberis and Lactococcus garvieae, which cause fish diseases, is selected and a peptide nucleic acid and a primer pair, which are specific for the genetic marker, are used to amplify and obtain melting curves having different fluorescences depending on bacterial species. Thus, bacteria that cause fish diseases can be discriminated and whether or not fish would be infected with the bacteria can be detected in a simple, rapid and accurate manner.

The invention discloses an LAMP primer for detecting needle mushroom surface Lactococcus. The LAMP primer consists of nucleotide sequences shown by SEQ ID No. 1 to SEQ ID No. 6. The needle mushroom Lactococcus mainly refers to Lactococcus lactis subsp. hordniae, Lactococcus lactis subsp. Lactis or Lactococcus garvieae strains. The invention also discloses a detection kit containing the LAMP primer and a corresponding detection method. The LAMP primer provided by the invention has strong specificity and high sensitivity, and has the advantages of simple method, high detection speed, easy observation, and no need for expensive equipment and professionals.

The invention relates to the field of microbial technology, and relates to a strain of Lactococcus garvieae and a feed additive produced therefrom. The feed additive is a solid microbial inoculum prepared from a liquid microbial inoculum through addition of proper nutrient substances, wherein the liquid microbial inoculum is prepared from Lactococcus garvieae SYP-B-301 through fermentation culture in a fermentation cylinder. The feed additive has a wide range of applications in animal husbandry and poultry raising such as pig raising, chicken raising, cattle raising and the like. The feed additive has a plurality of functions, through use of the feed additive, animal immunity after eating can be improved, animal diarrhoea rate and death rate can be reduced, the use of antibiotic drugs can be reduced, drug residues can be eliminated, production efficiency can be obviously improved, the raising cycle can be shortened, and feed can be effectively saved, so that income of farmers can be increased.

The invention relates to a Lactococcus garvieae LGHK2 and an application thereof. The strain is collected in the Guangdong Culture Collection Center on September 5, 2018, with the collection number ofGDMCC No. 60443, and the collection address of the 5th Floor, Building 59, Compound 100, Xianlie Middle Road, Guangzhou City, Guangdong Province. The Lactococcus garvieae LGHK2 has strong acid production capacity, and can be used for fermenting fresh shrimp shells, and the decalcification rate can reach 69.47-77.75 percent; when the Lactococcus garvieae LGHK2 is used for fermenting fresh shrimp heads, the pH value of the fermentation liquid can be as low as 3.3, the apparent hydrolysis degree can reach 40.74%, and the protein removal rate can reach 97.0%, so that the fermentation liquid has high-efficiency calcium and protein dissolving capability; and when the Lactococcus garvieae LGHK2 is applied to the fermentation treatment of shrimp wastes, the utilization rate of the shrimp wastes can be improved, and meanwhile, the environmental compatibility is better.

The present invention is lactococcus for producing beta-galactosidase and the production process of beta-galactosidase with the lactococcus strain. By means of preservation, rejuvenation and breeding of the lactococcus strain (CGMCC. No.1425) and optimized fermentation process, the present invention has short fermentation period and stable fermentation process to obtain beta-galactosidase with excellent high temperature activity and high enzyme activity. The product may be used widely in fermented milk product, beverage, food, medicine and other fields.

The present invention relates to a 2227-bp DNA fragment that confers antiphage activity. Two proteins encoded by this DNA sequence are responsible for the phage resistance phenotype. When introduced in Lactococcus lactis phage-sensitive strain, this DNA fragment aborts infection of phages of the 936 and P335 species.

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ ID NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.

A complete nutritional composition comprising Lactococcus strains or probiotic is provided for reducing the symptoms of allergies in different groups of patients such as allergies originating from food allergens in young children or infants and respiratory allergens in children, adults and household pets. Preferably the composition reduces symptoms of allergies (secondary prevention) while not significantly affecting sensitization (primary prevention). The composition comprises a probiotic of the genus Lactococcus.

Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and / or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and / or in the cytoplasmic membrane. A L. lactis strain, having an internal trehalose concentration of at least 10 mg per gram cells (w / w) is disclosed.

The invention relates to gamma-decalactone prepared based on biotransformation and a preparation method thereof. The gamma-decalactone is prepared by the following steps: inoculating yarrowia lipolytica into a fermentation culture medium, transforming and inoculating the obtained fermentation liquor into a transformation culture medium, carrying out transformation culture, adding oleic acid and oleic acid hydratase in batches in the process, and continuously carrying out transformation culture. The gamma-decalactone is produced through a biological fermentation and conversion technology with the waste grease mixture as the substrate, the problem that in an existing biological conversion technology, the substrate is single is solved with the waste grease mixture as the substrate, the waste grease mixture is rich in source, waste utilization is achieved, and the method is economical and environmentally friendly; meanwhile, the lactococcus gasseri genome DNA is used as a template, the oleic acid hydratase is obtained through PCR amplification, the activity of the oleic acid hydratase is improved, and the production yield of the gamma-decalactone is increased.